Ocular Therapeutix, Inc. to Present at 43rd Annual J.P. Morgan Healthcare Conference in January 2025
Ocular Therapeutix, Inc. to Present at 43rd Annual J.P. Morgan Healthcare Conference in January 2025
The conference will be held in San Francisco, CA.Ocular Therapeutix, Inc. will present at the J.P. Morgan Healthcare Conference on January 13, 2025, in San Francisco.
Ocular Therapeutix, Inc. 将于2025年1月13日在旧金山参加J.P. 摩根医疗健康会议。
Quiver AI Summary
Quiver AI 概要
Ocular Therapeutix, Inc. announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco, CA. The presentation will take place on January 13 at 5:15 PM PT, featuring Pravin U. Dugel, MD, the Executive Chairman, President, and CEO of the company. Ocular Therapeutix focuses on developing innovative therapies for retinal diseases, including its product candidate AXPAXLI (axitinib intravitreal implant), currently in Phase 3 trials for wet age-related macular degeneration. Their pipeline also includes the FDA-approved product DEXTENZA and another candidate, PAXTRAVA, which is in Phase 2 for open-angle glaucoma. The presentation will be accessible via the company's website.
Ocular Therapeutix, Inc. 宣布将参加2025年1月13日至16日在加州旧金山举行的第43届年度J.P. 摩根医疗健康会议。演讲将于1月13日下午5:15（太平洋时间）进行，由公司执行董事长、总裁兼首席执行官Pravin U. Dugel博士主讲。Ocular Therapeutix专注于开发用于视网膜疾病的创新疗法，包括其候选产品AXPAXLI（阿昔替尼玻璃体内植入物），目前正在进行湿性年龄相关性黄斑变性Phase 3临床试验。他们的产品线还包括FDA批准的产品DEXTENZA和另一个候选药物PAXTRAVA，后者正在进行开角型青光眼的Phase 2临床试验。演讲将可通过公司的网站访问。
Potential Positives
潜在的积极因素
- Ocular Therapeutix will present at the prestigious 43rd Annual J.P. Morgan Healthcare Conference, highlighting the company's visibility and commitment to engaging with investors and stakeholders.
- The presentation will be led by the Executive Chairman, President, and CEO, Dr. Pravin U. Dugel, which emphasizes strong leadership representation at major industry events.
- Ocular Therapeutix's product candidate AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration, indicating progress in their pipeline and potential market impact.
- The company continues to leverage its proprietary ELUTYX technology in its product offerings, showcasing innovation that may enhance treatment options in ophthalmic medicine.
- Ocular Therapeutix将在第43届年度J.P. 摩根医疗健康会议上展示，突显公司与投资者和利益相关者交流的可见性和承诺。
- 演讲将由执行董事长、总裁兼首席执行官Pravin U. Dugel博士主讲，强调在主要行业活动中强大的领导代表性。
- Ocular Therapeutix的产品候选药物AXPAXLI目前正在进行湿性年龄相关性黄斑变性Phase 3临床试验，显示出他们产品线的进展和潜在市场影响。
- 公司继续利用其专有的ELUTYX技术进行产品提供，展示可能增强眼科医学治疗选择的创新。
Potential Negatives
潜在负面因素
- There is no mention of any recent achievements or positive developments regarding the current clinical trials, which may raise concerns about the progress and efficacy of their lead product candidate, AXPAXLI.
- The press release lacks financial performance metrics or guidance, which could signal that the company is facing challenges that it is not publicly addressing.
- The announcement is primarily focused on an upcoming conference presentation, suggesting that the company may not have immediate newsworthy developments to share, potentially signaling stagnation in their operational updates.
- 没有提到任何关于当前临床试验的近期成就或积极进展，这可能引发人们对他们的主要产品候选者AXPAXLI的进展和有效性的担忧。
- 新闻稿缺乏财务表现指标或指引，这可能表明公司面临没有公开应对的挑战。
- 该公告主要集中于即将到来的会议演示，表明公司可能没有可以立即分享的重大新闻，可能暗示其运营更新的停滞。
FAQ
常见问题
What is the date of Ocular Therapeutix's presentation at the J.P. Morgan Healthcare Conference?
Ocular Therapeutix在J.P. 摩根医疗会议上的演讲日期是什么？
Ocular Therapeutix will present on January 13, 2025.
Ocular Therapeutix将在2025年1月13日进行演讲。
Where will the J.P. Morgan Healthcare Conference take place?
J.P.摩根医疗健康会议将在哪里举行？
The conference will be held in San Francisco, CA.
会议将在加利福尼亚州旧金山举行。
Who will present for Ocular Therapeutix at the conference?
谁将代表Ocular Therapeutix在会议上演讲？
Pravin U. Dugel, MD, will present as the Executive Chairman, President, and CEO.
Pravin U. Dugel 医生将作为执行主席、总裁和首席执行官进行演讲。
How can I access the live presentation?
我如何访问直播演讲？
The live presentation can be accessed on the Ocular Therapeutix website under the Events and Presentations section.
可以通过Ocular Therapeutix网站的活动与演讲部分访问直播演讲。
What is AXPAXLI and its current clinical trial stage?
AXPAXLI是什么，它目前的临床试验阶段是什么？
AXPAXLI is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
AXPAXLI正在进行针对湿性年龄相关性黄斑变性（湿性AMD）的第三阶段临床试验。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免责声明：这是由GlobeNewswire分发的新闻稿的人工智能生成摘要。用于总结这份稿件的模型可能会出错。请在这里查看完整发布。
$OCUL Insider Trading Activity
$OCUL内部交易活动
$OCUL insiders have traded $OCUL stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
$OCUL内部人士在过去6个月内在公开市场交易$OCUL股票6次。其中，0次为购买，6次为出售。
Here's a breakdown of recent trading of $OCUL stock by insiders over the last 6 months:
以下是$OCUL股票在过去6个月内被内部人士交易的详细情况：
- JEFFREY S. HEIER (Chief Scientific Officer) sold 2,948 shares.
- PETER KAISER (Chief Development Officer) sold 2,897 shares.
- SANJAY NAYAK (Chief Strategy Officer) has traded it 2 times. They made 0 purchases and 2 sales, selling 3,646 shares.
- PRAVIN DUGEL (See Remarks) has traded it 2 times. They made 0 purchases and 2 sales, selling 41,560 shares.
- 杰弗里·希尔（首席科学官）出售了2,948股。
- 彼得·凯撒（首席发展官）出售了2,897股。
- 桑贾伊·纳亚克（首席策略官）交易了2次。他们没有进行购买，进行了2次出售，售出3,646股。
- PRAVIN DUGEL (见备注) 交易了2次。他们没有购买，出售了41,560股。
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
要跟踪内部交易，请查看Quiver Quantitative的内部交易特斯拉-仪表。
$OCUL Hedge Fund Activity
ocular therapeutix 对冲基金活动
We have seen 76 institutional investors add shares of $OCUL stock to their portfolio, and 95 decrease their positions in their most recent quarter.
我们看到76家机构投资者在最近一个季度新增了$OCUL股票的股份，95家减少了他们的持仓。
Here are some of the largest recent moves:
以下是最近的一些重大变动：
- ASSENAGON ASSET MANAGEMENT S.A. added 2,825,756 shares (+inf%) to their portfolio in Q3 2024
- GREAT POINT PARTNERS LLC removed 1,728,723 shares (-100.0%) from their portfolio in Q2 2024
- LOGOS GLOBAL MANAGEMENT LP removed 1,650,000 shares (-32.0%) from their portfolio in Q3 2024
- ACUTA CAPITAL PARTNERS, LLC removed 1,581,059 shares (-57.1%) from their portfolio in Q3 2024
- ARTISAN PARTNERS LIMITED PARTNERSHIP added 1,056,092 shares (+inf%) to their portfolio in Q3 2024
- WOODLINE PARTNERS LP added 1,000,000 shares (+inf%) to their portfolio in Q3 2024
- INVESCO LTD. added 709,573 shares (+1545.9%) to their portfolio in Q3 2024
- ASSENAGON 资产管理 S.A. 在2024年第三季度新增了2,825,756股 (+inf%) 的股份。
- GREAt POINt PARTNERS LLC 在2024年第二季度移除了1,728,723股 (-100.0%) 的股份。
- LOGOS 全球资产管理 LP 在2024年第三季度移除了1,650,000股 (-32.0%) 的股份。
- ACUTA CAPITAL PARTNERS, LLC 在2024年第三季度从其投资组合中减少了1,581,059股（-57.1%）
- ARTISAN PARTNERS LIMITED PARTNERSHIP 在2024年第三季度向其投资组合中增加了1,056,092股（+无穷大%）
- WOODLINE PARTNERS LP 在2024年第三季度向其投资组合中增加了1,000,000股（+无穷大%）
- INVESCO LTD. 在2024年第三季度向其投资组合中增加了709,573股（+1545.9%）
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
要跟踪对冲基金的股票投资组合，请查看Quiver Quantitative的机构持有情况仪表。
Full Release
完整发布
BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present at the 43
rd
Annual J.P. Morgan Healthcare Conference to be held January 13-16, 2025 in San Francisco, CA.
马萨诸塞州贝德福德，2024年12月10日（环球新闻报道）-- Ocular Therapeutix, Inc.（纳斯达克：OCUL，"Ocular"，"公司"）是一家致力于通过开发和商业化创新疗法来改善现实世界视力的生物制药公司，专注于视网膜疾病和其他眼部疾病，今天宣布该公司将出席第43届会议
rd
2025年1月13日至16日在加州旧金山举行年度J.P.摩根医疗保健会议。
43
rd
Annual J.P. Morgan Healthcare Conference Presentation Details
Presentation Date: Monday, January 13, 2025
Presentation Time: 5:15 PM PT
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: San Francisco, CA
43
rd
年度J.P.摩根医疗保健会议演讲详情
演讲日期：2025年1月13日，星期一
演讲时间：太平洋时间下午5:15
演讲者：Pravin U. Dugel医学博士，执行主席，总裁兼首席执行官
地点：加州旧金山
The live presentation can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.
通过访问Ocular Therapeutix网站的投资者关系页面上的活动与报告部分，也可以访问直播演示。
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI (axitinib intravitreal implant, also known as OTX-TKI), Ocular's product candidate for retinal disease, is based on its ELUTYX proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
关于Ocular Therapeutix公司
Ocular Therapeutix公司是一家生物制药公司，致力于通过开发和商业化创新疗法来改善现实世界的视力，主要针对视网膜疾病和其他眼部疾病。AXPAXLI（阿西替尼玻璃体内植入物，也称为OTX-TKI）是Ocular针对视网膜疾病的产品候选，基于其ELUTYX专有的生物可吸收水凝胶制剂技术。AXPAXLI目前正在进行针对湿性年龄相关性黄斑变性（湿性AMD）的三期临床试验。
Ocular's pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA
, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Ocular的产品线还利用ELUTYX技术，其商业产品DEXTENZA
是一种FDA批准的皮质类固醇，用于治疗眼科手术后的眼部炎症和疼痛以及与过敏性结膜炎相关的眼部瘙痒；还包括其产品候选PAXTRAVA（travoprost房水内植入物或OTX-TIC），该产品目前正在进行针对开角型青光眼或眼压升高的二期临床试验。
Follow the Company on its website, LinkedIn, or X.
在公司官网、LinkedIn或X上关注公司。
The Ocular Therapeutix logo and DEXTENZA
are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI, PAXTRAVA, ELUTYX, and Ocular Therapeutix are trademarks of Ocular Therapeutix, Inc.
Ocular Therapeutix的标志和DEXTENZA
是Ocular Therapeutix公司的注册商标。AXPAXLI、PAXTRAVA、ELUTYX和Ocular Therapeutix是Ocular Therapeutix公司的商标。
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
投资者与媒体
Ocular Therapeutix, Inc.
比尔·斯拉特里
副总裁，投资者关系
bslattery@ocutx.com
